Opinion|Videos|February 11, 2025
Pirtobrutinib in R/R CLL: Can It Be Used in the Second-Line Setting?
Panelists discuss how pirtobrutinib is increasingly being considered as a second-line option in relapsed/refractory chronic lymphocytic leukemia (R/R CLL), particularly for patients who have developed resistance or intolerance to covalent Bruton tyrosine kinase (BTK) inhibitors, though the optimal positioning of this noncovalent BTK inhibitor continues to evolve as more real-world experience accumulates.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Panelists discuss how pirtobrutinib is increasingly being considered as a second-line option in relapsed/refractory chronic lymphocytic leukemia (R/R CLL), particularly for patients who have developed resistance or intolerance to covalent Bruton tyrosine kinase (BTK) inhibitors, though the optimal positioning of this noncovalent BTK inhibitor continues to evolve as more real-world experience accumulates.
Advertisement
Related to this article
Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.
The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.
A UCLA-led study suggests routine mammograms or other breast imaging may not benefit women after double mastectomy for DCIS.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5